Literature DB >> 23138775

[Adjuvant radiotherapy following lymphadenectomy for malignant melanoma significantly improves local control].

G Goldner1.   

Abstract

Entities:  

Year:  2013        PMID： 23138775     DOI： 10.1007/s00066-012-0248-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  5 in total

1.  Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma.

Authors:  C J O'Brien; K Petersen-Schaefer; G N Stevens; P C Bass; P Tew; V J Gebski; J F Thompson; W H McCarthy
Journal:  Head Neck       Date:  1997-10       Impact factor: 3.147

2.  A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06.

Authors:  Bryan H Burmeister; B Mark Smithers; Elizabeth Burmeister; Kathryn Baumann; Sidney Davis; Hedley Krawitz; Carol Johnson; Nigel Spry
Journal:  Radiother Oncol       Date:  2006-10-24       Impact factor: 6.280

3.  Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas?

Authors:  D Fuhrmann; A Lippold; F Borrosch; U Ellwanger; C Garbe; L Suter
Journal:  Br J Dermatol       Date:  2001-01       Impact factor: 9.302

4.  Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study.

Authors:  E T Creagan; R E Cupps; J C Ivins; D J Pritchard; F H Sim; E H Soule; J R O'Fallon
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

5.  Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.

Authors:  Bryan H Burmeister; Michael A Henderson; Jill Ainslie; Richard Fisher; Juliana Di Iulio; B Mark Smithers; Angela Hong; Kerwin Shannon; Richard A Scolyer; Scott Carruthers; Brendon J Coventry; Scott Babington; Joao Duprat; Harald J Hoekstra; John F Thompson
Journal:  Lancet Oncol       Date:  2012-05-09       Impact factor: 41.316
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.